Quetiapine, an atypical antipsychotic with antagonistic effects on dopamine D2 and serotonin 5-HT2A receptors, has shown potential in managing cluster headaches by modulating neurotransmitter activity and reducing neurogenic inflammation. Its mechanism involves central nervous system receptor blockade that may interrupt pain signaling pathways and provide prophylactic benefits for cluster headache patients.